After shares of Novo Nordisk (NVO) fell throughout the last year, the more recent drop may be its last. The company, along with its rival Eli Lilly (LLY), will offer its obesity drug for $499 per ...

The Ministry of Health, through the Pharmacy and Poisons Board (PPB), has issued a cautionary advisory to members of the ...

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of ...

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between ...

Novo Nordisk, the company that makes Ozempic, is now offering its popular diabetes drug to eligible patients for less than half the price. The drugmaker says patients who pay for the medication on ...

We do believe that people who face high out-of-pocket costs need more options,” said Kevin Donahoe, diabetes marketing chief for Novo Nordisk. Plus: a look at the drugmaker's alliance with GoodRx; how ...

Copycat versions of popular drugs like Ozempic and Mounjaro have continued to proliferate in a postshortage era, with some ...